Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin with Metformin

PHASE3RecruitingINTERVENTIONAL

Enrollment

582

Participants

Timeline

Start Date

August 27, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

T2DM

Interventions

DRUG

CT-L03 Group 1

tablets, QD, oral administration

DRUG

CT-L03 Group 2

tablets, QD, oral administration

DRUG

Placebo

tablets, QD, oral administration

DRUG

Empagliflozin

tablet, QD, oral administration

DRUG

Metformin

tablets, oral administration

Trial Locations (1)

RECRUITING

Celltrion, Incheon